-
Alectinib (INN), sold
under the
brand name Alecensa, is an
anticancer medication that is used to
treat non-small-cell lung
cancer (NSCLC). It
blocks the...
-
alectinib in efficacy,
while being active against some
resistant mutations such as the
common G1202R
mutation that
provides resistance to
alectinib....
-
which can be
treated with ALK
inhibitors crizotinib, or its
successors alectinib, brigatinib, and ceritinib.
Those treated with ALK
inhibitors who relapse...
- and vomiting,
licensed by
Eisai Co. and
Helsinn Therapeutics.
Alecensa (
alectinib), for ALK-positive non-small cell lung cancer.
Aloxi (palonosetron), for...
- chemotherapy. In
February 2016, the J-ALEX
phase III
study comparing alectinib with
crizotinib ALK-positive
metastatic NSCLC was
terminated early because...
- to
treat metastatic melanoma caused by BRAF mutation. 2015:
Alecensa (
alectinib):
Treatment for non-small cell lung
cancer (NSCLC). 2016:
Venclexta (venetoclax):...
- 2035 MA 2006
Linagliptin 2011 2031 SM 2007
Apixaban 2012 2032 SM 2007
Alectinib 2014 2014 SM 2007
Sofosbuvir 2007,
Raymond F. Schi****. N/A N/A N/A SM...
-
Dabrafenib L01EC03
Encorafenib L01ED01
Crizotinib L01ED02
Ceritinib L01ED03
Alectinib L01ED04
Brigatinib L01ED05
Lorlatinib L01EE01
Trametinib L01EE02 Cobimetinib...
-
Vemurafenib Hoffmann-La
Roche Erdheim-Chester
disease with BRAF V600
mutation Alectinib Hoffmann-La
Roche ALK-positive,
metastatic non-small cell lung cancer...
-
Regorafenib Semaxanib Sorafenib Sunitinib Tivozanib Toceranib Vandetanib ALK
Alectinib Brigatinib Ceritinib Crizotinib Lorlatinib RET inhibitors: Entrectinib...
